Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Nasopharyngeal Carcinoma 7Breast Neoplasms 6Esophageal Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Liver Neoplasms 3Neoplasm Metastasis 2Locally Advanced Rectal Cancer 2Carcinoma, Non-Small-Cell Lung 2Adrenocortical Carcinoma 2Unresectable Gallbladder Cancer 1Turcot syndrome 1Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Non Squamous Non Small Cell Lung Cancer 1Nasopharyngeal Neoplasms 1Multiple Primary Lung Cancer 1Melanoma 1Locally Advanced or Metastatic Solid Tumors 1Liver Diseases 1Leukemia, Myeloid, Acute 1Her-2 Negative Breast Cancer 1

Interventions

pembrolizumab 3toripalimab 1tislelizumab 1spartalizumab 1sintilimab 1camrelizumab 1Taxes 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Locally Advanced or Metastatic Solid Tumors × camrelizumab × Clear all
NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
40 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡